Pediatric Clinical Trials
Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which regimen of combination chemotherapy is most effective for lymphoblastic lymphoma.
PURPOSE: This randomized phase III trial is studying different regimens of combination chemotherapy to compare how well they work in treating children or adolescents with newly diagnosed stage III or stage IV lymphoblastic lymphoma.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: vincristine sulfate
- radiation: radiation therapy
- drug: cyclophosphamide
- drug: cytarabine
- drug: daunorubicin hydrochloride
- drug: dexamethasone
- drug: doxorubicin hydrochloride
- drug: leucovorin calcium
- drug: mercaptopurine
- drug: methotrexate
- drug: prednisone
- drug: thioguanine
- drug: asparaginase
Eligibility
DISEASE CHARACTERISTICS:
- Newly diagnosed disseminated lymphoblastic lymphoma or localized lymphoblastic
lymphoma*
- Less than 25% tumor cells in the bone marrow
- Previously untreated (prior intrathecal cytarabine allowed if protocol therapy
begins within 72 hours)
- Stage III or IV disease
- NOTE: *Localized lymphoblastic lymphoma is closed to accrual as of 10/2005
PATIENT CHARACTERISTICS:
Age:
- 1 to 30
Performance status:
- Not specified
Life expectancy:
- Not specified
Hematopoietic:
- Not specified
Hepatic:
- Not specified
Renal:
- Not specified
Cardiovascular:
- Adequate cardiac function
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- See Disease Characteristics
Endocrine therapy:
- Emergency steroid therapy (if required) must be started within 72 hours prior to
protocol therapy
Radiotherapy:
- Emergency radiotherapy (if required) must be started within 72 hours prior to protocol
therapy
Surgery:
- Not specified
Other:
- No other prior therapy except for emergency treatment of airway obstruction and/or
superior vena cava syndrome
Ages Eligible for Study
1 Year - 30 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Peds Hem/Onc CRAs
650-723-5535
Not Recruiting